Back to the main directory
EarningsReview / Equity
- HKEX (388 HK) by HSBC
- ASE Technology Holding (3711 TT) by HSBC
- Keep calm and carry on by BNP Paribas Exane
- Worth the wait? by BNP Paribas Exane
- Q1 2025 Conference call feedback by BNP Paribas Exane
- Guidance maintained, even with acquisitions, wait and see mode by BNP Paribas Exane
- Redeia 1Q25 - First take by BNP Paribas Exane
- Q1 25 results first take by BNP Paribas Exane
- Reassuring Q1 print, relief expected by BNP Paribas Exane
- Q125 results and 15 questions for management by BNP Paribas Exane
- US slowdown raises doubts, overshadowing strong start by BNP Paribas Exane
- First Take On Western Digital’s FQ3:25 Earnings by BNP Paribas Exane
- L&F (066970 KS) by HSBC
- Capitec (CPI SJ) by HSBC
- On track despite uncertainties by BNP Paribas Exane
- US Industry Dashboard: Non-Alc Bevs More Resilient Thru 4/19; Industry Growth Most +ve for MNST, CELH, KO, KDP; -ve for CLX; S. Snacks Share Now Also an Issue for PEP by BNP Paribas Exane
- CTG Duty Free (1880 HK/601888 CH) by HSBC
- Itaú BBA on Engie Energia: Strong results in Chile lead to a better-than-expected 1Q25 by Itau
- DOGE vs. Cyber: Federal integrator bullish on Zero Trust by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Closing the Loop on Closed-Toe by BNP Paribas Exane
- Blocking and tackling by BNP Paribas Exane
- Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highlight in Q1 by DnB Markets
- Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression by DnB Markets
- Embla Medical (Buy, TP: DKK35.50) - Better start to the year than expected by DnB Markets